Thalassemia Market By Treatment (Medication {Deferasirox, Deferiprone, Deferoxamine, Other}, Iron Chelation Therapy {Oral Iron Chelators, Injectable Iron Chelators}, Bone Marrow/Stem Cell Transplantation, Blood Transfusions, Gene Therapy), By Diagnosis (Prenatal Testing, {Amniocentesis, Chorionic Villus Sampling (CVS)}, Genetic Testing, Blood Tests), By Type (Alpha Thalassemia, Beta Thalassemia), By End-User (Hospitals, Specialty Clinics, Diagnostic Laboratories), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Report Coverage:

By Treatment

• Medication
  • Deferasirox
  • Deferiprone
  • Deferoxamine
  • Other
• Iron Chelation Therapy
  • Oral Iron Chelators
  • Injectable Iron Chelators
• Bone Marrow
• Blood Transfusions
• Gene Therapy

By Diagnosis

• Prenatal Testing
  • Amniocentesis
  • Chorionic Villus Sampling (CVS)
• Genetic Testing
• Blood Tests

By Type

• Alpha Thalassemia
• Beta Thalassemia

By End User

• Hospitals
• Specialty Clinics
• Diagnostic Laboratories
• Research Institutes

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of the Middle East & Africa

List of Companies:

• CRISPR Therapeutics
• Bluebird Bio
• Sangamo Therapeutics
• Beam Therapeutics
• Kanglin Biotech
• Novartis
• Fate Therapeutics
• Gilead Sciences
• Editas Medicine
• Addgene
• Celgene (Bristol-Myers Squibb)
• Shire (now part of Takeda)
• Agios Pharmaceuticals
• Magenta Therapeutics
• Regeneron Pharmaceuticals
• Biogen
• Terumo BCT
• Astellas Pharma